Page 46 - Pharma Sector

Biocon net rises 11% in Q2 to Rs 188 cr, revenue up 10% at Rs 1,945 cr

Revenue growth was primarily driven by good performance of its research services and biosimilars business segments

New-age pharmacy start-ups tap 'kirana' networks, eye US market

New entrants in the largely unorganised Indian pharmaceuticals market are trying out innovative ways to tap a vast market that lies in hinterland

Cipla to sell Eli Lilly's insulin products Humalog, Trulicity in India

Only 3 firms - Novo Nordisk, Sanofi, and Eli Lilly - supply insulin to patients in the US. These three companies, commonly called the 'Big Three', control over 90 per cent of the global insulin market

N Govindarajan steps down as Aurobindo Pharma managing director

Govindarajan has decided to step down due to "personal reasons", Aurobindo Pharma said in a regulatory filing

RPG Life Sciences hits record high, zooms 51% so far in September

The domestic formulations business of the company will continue to focus on building chronic therapies, expanding specialty portfolio and life cycle management of current legacy products

Vivek Chaand Sehgal resigns as director from Sun Pharmaceutical board

Drug firm Sun Pharmaceutical Industries on Friday said Vivek Chaand Sehgal has resigned as an independent director of the company with effect from September 1.

Lupin, Glenmark shift focus to inhalation and nasal Covid-19 drugs

Lupin working on remdesivir powder inhaler; Glenmark to do trials on Nitric Oxide Nasal Spray

Pharma industry to surpass $60 bn by FY24 from $45 bn in FY21: Report

The pandemic push will lead to an 11 per cent annual growth for the pharma sector over the next two years and help it surpass USD 60 billion from around USD 45 billion in FY21, according to a report.

3 reasons why pharma's 'underperformer' tag at markets could change soon

Resolution of supply chain issues, defensive buying and index inclusion are triggers

Aurobindo Pharma's Rs 450-cr deal to acquire 51% in Cronus Pharma cancelled

Aurobindo Pharma Ltd on Friday said its Rs 450-crore deal to acquire 51 per cent stake in Cronus Pharma Specialities India Pvt Ltd (Cronus) has been cancelled

Shapoorji Mistry and Dadachanji-led Kaisha Group to enter pharma space

Plans to launch brands in antacids, analgesics, blood thinners, bump up hiring

Exporters want steel, pharmaceuticals sectors under RoDTEP scheme

The RoDTEP guidelines do not include sectors such as steel, organic & inorganic chemicals, and pharma under the scheme

Serum Institute buys 50% stake in pharma packaging firm Schott Kaisha

The joint venture is for pharmaceutical packaging

JB Chemicals & Pharmaceuticals posts Rs 119 crore profit April-June

Drug firm JB Chemicals & Pharmaceuticals on Thursday reported a consolidated net profit of Rs 119.05 crore for the quarter ended on June 30, 2021. The company had posted a net profit of Rs 119.50 crore for the corresponding period of the previous fiscal, JB Chemicals & Pharmaceuticals said in a filing to BSE. Consolidated revenue from operations of the company stood at Rs 606 crore for the quarter under consideration. It was Rs 522.3 crore for the same period a year ago, it added. "The organisation continues its strong performance well in the first quarter of the financial year. On the domestic front, we are one of the fastest growing companies in the industry," JBCPL CEO and Wholetime Director Nikhil Chopra said. While demand trends in international business continue to be volatile (given the COVID situation); the company's key markets like the US, South Africa have outperformed and even Russia/ CIS are seeing gradual signs of revival, he added. Shares of JB Chemicals & ..

Glenmark Life Sciences slips below issue price as stock falls 5%

On Friday, August 6, 2021, the company had made a quiet debut on the bourses as the shares listed at Rs 751.10 on the BSE

Windlas Biotech IPO oversubscribed 22.46 times on closing day

The initial public offer of Windlass Biotech, a manufacturer of pharmaceutical formulations, was subscribed 22.46 times on Friday, the closing day for subscription. The three-day IPO received bids for 13,77,39,750 shares against 61,36,252 shares on offer, as per NSE data. The category for Qualified Institutional Buyers(QIBs) was subscribed 24.40 times, non-institutional investors 15.73 times, and retail individual investors(RIIs) 24.27 times. The initial public offer had a fresh issue of up to Rs 165 crore and an offer for sale of up to 51,42,067 equity shares. The Rs 401.53-crore offer had a price range of Rs 448-460 per share. Windlas Biotech on Tuesday raised over Rs 120 crore from anchor investors. The proceeds from the IPO will be utilised for purchasing of equipment required for capacity expansion of the facility at Dehradun Plant-IV and addition of injectables dosage capability at the facility at Dehradun Plant-II. It will also be used for funding incremental working capi

Aurobindo Pharma channelising efforts to commercialise Covid-19 vaccine

The Hyderabad-based drug major is looking to develop products with higher complexity, focus on injectables business and expand business in high growth markets like China.

Ind Swift Labs tanks 16% on selling API business to PI Industries

PI Ind said the purchase consideration of Rs 1,530 crore will be paid in all-cash and funded from the proceeds of the completed QIP and internal accruals

Sun Pharma posts consolidated net profit of Rs 1,444 crore in Q1

The company had posted a net loss of Rs 1,655.60 crore for the corresponding period of the previous fiscal

Sun Pharma rallies 9%, hits over 4-year high on strong June quarter results

The management said Sun Pharma witnessed a strong Q1, driven by a combination of robust core business growth, low base and some sale of Covid products